Moreau, Philippe <br/><br/>
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.  [electronic resource] 

 -  The Lancet. Oncology  07 2018 
 - 953-964 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(18)30354-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Dexamethasone--therapeutic use<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Lenalidomide--therapeutic use<br/>Male<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Oligopeptides--therapeutic use<br/>Prognosis<br/>Proteasome Inhibitors--therapeutic use<br/>Recurrence<br/>Risk Assessment<br/>Survival Analysis<br/>Treatment Outcome